Vortioxetine

Generic Name: Vortioxetine

Brand Names: Brintellix, Trintellix

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₂N_₂S

CAS Number: 508233-74-7

Unique Ingredient Identifier: 3O2K1S3WQV

Background: Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.

Indication: 用于治疗重度抑郁症成人患者。

Associated Conditions: Major Depressive Disorder (MDD)

Clinical Trials

MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users

Phase 4

Conditions: Depression
Relapse
Cognitive Impairment

Interventions: Drug: Vortioxetine

First Posted Date: 2019-02-05

Last Posted Date: 2019-11-29

Lead Sponsor: Sir Run Run Shaw Hospital

Target Recruit Count: 220

Registration Number: NCT03830827

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine
Drug: Sertraline
Drug: citalopram
Drug: Escitalopram
Drug: Paroxetine
Drug: Fluoxetine
Drug: Fluvoxamine

First Posted Date: 2018-12-19

Last Posted Date: 2023-05-19

Lead Sponsor: Azienda Ospedaliera Universitaria Integrata Verona

Target Recruit Count: 362

Registration Number: NCT03779789

Locations: 🇮🇹
Azienda Ospedaliera Universitaria Mater Domini, Università Magna Grecia, Catanzaro, Italy
🇮🇹
Sapienza Università di Roma, Dipartimento di Neurologia e Psichiatria, Roma, Italy
🇮🇹
Azienda Ospedaliera Universitaria Verona, Verona, Italy

Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo infusion
Drug: Vortioxetine infusion 25 mg
Drug: Vortioxetine tablets 10 mg/day
Drug: Placebo tablets

First Posted Date: 2018-12-06

Last Posted Date: 2019-08-29

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 80

Registration Number: NCT03766867

Locations: 🇧🇬
MHAT "Dr. Hristo Stambolski", EOOD (BG1001), Kazanlak, Bulgaria
🇧🇬
State Psychiatric Hospital "Sv. Ivan Rilski" (BG1009), Novi Iskar, Bulgaria
🇧🇬
Mental Health Centre 'Prof. Dr. Ivan Temkov', EOOD (BG1004), Burgas, Bulgaria

and more 10 locations

Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression

Phase 2

Conditions: Bipolar Disorder Depression

Interventions: Drug: Placebo
Drug: Vortioxetine

First Posted Date: 2018-07-26

Last Posted Date: 2018-08-10

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 100

Registration Number: NCT03598868

Locations: 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

Phase 4

Withdrawn

Conditions: Major Depressive Disorder
Type2 Diabetes

Interventions: Drug: Vortioxetine

First Posted Date: 2018-07-10

Last Posted Date: 2022-11-29

Lead Sponsor: Todd Doyle

Registration Number: NCT03580967

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Real-life Effectiveness of Vortioxetine in Depression

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2018-06-13

Last Posted Date: 2021-05-27

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 992

Registration Number: NCT03555136

Locations: 🇺🇸
Pharmacology Research Institute (US0045), Newport Beach, California, United States
🇺🇸
Maxblue Institute (US0038), Hialeah, Florida, United States
🇺🇸
Northwest Behavioral Research Center (US0007), Marietta, Georgia, United States

and more 103 locations